This study reports on a preliminary structure-activity relationship exploration of 4-aryliden-2-methyloxazol-5(4H)-one-based compounds as MAGL/FAAH inhibitors. Our results highlight that this scaffold may serve for the development of selective MAGL inhibitors. A 69-fold selectivity against MAGL over FAAH was achieved for compound 16b (MAGL and FAAH IC 50 = 1.6 and 111 µM, respectively). Furthermore, the best compound behaved as a reversible ligand and showed promising antiproliferative activity in cancer cells.
Introduction
The endocannabinoid system is involved in a large number of physiopathological processes, such as the regulation of cellular proliferation, pain sensation, appetite and cognition 1 . It is widespread in the mammalian tissues and it acts as a pro-homeostatic effector being activated following transient or chronic perturbation of homeostasis and locally regulating the levels and action of other chemical signals 2 . Among the various reported endogenous lipids with endocannabinoid-like activity, 2-arachidonoylglycerol (2-AG) and arachidonoylethanolamide (AEA) are considered the two most important ligands of the CB 1 and CB 2 cannabinoid receptors. The signaling functions of AEA and 2-AG are terminated by enzymatic hydrolysis, which is mainly mediated by the fatty acid amide hydrolase (FAAH) and monoacylglicerol lipase (MAGL), respectively 3 . The in vivo cannabinometic effects of the endocannabinoids are rather weak, due to the fact that they are rapidly inactivated by cellular reuptake followed by intracellular hydrolysis. However, an increase in the level of endocannabinoids, caused by a reduction of their metabolism promoted by FAAH or MAGL, could lead to several advantageous effects 4 . MAGL inhibition in the periphery produces CB 1 -dependent antinociceptive effects of noxious chemical, inflammatory, thermal, and neuropathic pain in mouse models 5 . Genetic and pharmacological blockades of MAGL also exhibit anti-inflammatory effects in the brain and neuroprotective effects for Parkinson's and Alzheimer's disease in mouse models 6 .
Furthermore, other studies demonstrated that the inhibition of MAGL also exerts anti-anxiety 3 responses 7 and can be useful for modulating opiate drug dependence 8 . Finally, MAGL is upregulated in aggressive cancer cells and primary tumors and its inhibition in aggressive breast, ovarian, and melanoma cancer cells impairs cell migration, invasiveness, and tumorigenicity 9 .
Three different types of MAGL inhibitors have been reported in literature so far: 1) compounds that bind the enzyme covalently and irreversibly; 2) compounds that bind covalently and reversibly;
3) compounds that bind non-covalently. Among the compounds that bind covalently, two different sub-types are reported, those that bind the nucleophilic serine 122 (S122) and those that target the cysteines of the enzyme 3 . This last class of MAGL inhibitors generally shows a high selectivity against FAAH; however, this selectivity over other enzymes containing cysteine residues in the binding site still needs to be verified. Regarding the MAGL inhibitors that bind the nucleophilic S122, a wide number of compounds have been reported in literature, but only few show high selectivity against FAAH. One of the most promising ligands was developed by Cravatt and coworkers, and it consists of a carbamate derivative that behaves as an irreversible nanomolar inhibitor (JZL-184, Figure 1 ) and displays a high selectivity for MAGL versus FAAH enzymes 10 .
In the last 5 years this compound has been used as a reference molecule for a wide number of in vitro and in vivo experimental studies. Very recently, Laitinen and co-workers, by combining the 1,2,4-triazole leaving group together with the aromatic benzodioxolyl moiety, reported the development of compound JJKK-048 ( Figure 1) 
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, which is probably the most active and selective irreversible MAGL inhibitor ever reported. CAY10499 ( Figure 1 ) is a known irreversible inhibitor of both MAGL and FAAH enzymes 12 . Although CAY10499 is a carbamate-based inhibitor, just like many other compounds interacting with the enzymes of the endocannabinoid system, further studies revealed that the 5-methoxy-1,3,4-oxadiazol-2(3H)-one ring is the main responsible for MAGL inhibition. The structure-activity relationships of this compound and further MALDI-and SELDI-TOF mass spectrometry analyses of analogous compounds [12] [13] On the basis of the ability of the 5-methoxy-1,3,4-oxadiazol-2(3H)-one moiety (I, Figure 2 ) to interact with the catalytic serine of MAGL, we decided to design and synthesize compounds possessing a similar 2-methyl-4-methyleneoxazol-5(4H)-one scaffold (II, Figure 2 ). Both structures are based on a cyclic carbamate or lactone moiety, which can be opened in the presence of a nucleophile; moreover, the geometry of the C-N bond, in which the nitrogen atom is present in position 3 of the 5-methoxy-1,3,4-oxadiazol-2(3H)-one cycle, could be mimicked by the 4-arylidene portion of the 2-methyl-4-methyleneoxazol-5(4H)-one scaffold. Therefore, a series of three new exploratory small compounds 2, 3 and 4 (Schemes 1 and 2), were initially synthesized to 5 determine which kind of aromatic portion (Ar, Figure 2 ), such as phenyl (2) or heteroaromatic fivemembered cycle (3 and 4), was more suitable for obtaining good inhibition levels on MAGL.
Further developments of this chemical class were carried out and nine new compounds (16a-c, 17a-c and 18a-c, Scheme 3) were obtained by introducing unsubstituted or para-substituted (fluoro and methoxy) phenyl rings in the aromatic ring of compound 2. Finally, in order to verify whether the 2-methyloxazol-5(4H)-one moiety was necessary for the activity on MAGL, we synthesized and tested a compound containing the opened cycle (19, Scheme 4). 
Results and discussion

Chemistry
The synthetic pathways for obtaining the target benzylidene-oxazolone compounds 2, 3, 4, 16a-c, 17a-c, 18a-c are outlined in Schemes 1, 2 and 3. Benzylidene-oxazolones were obtained in one 20 . In particular, bromo-derivatives 10-12 were treated with the appropriate unsubstituted (R 1 = H; Scheme 3) or para-substituted (R 1 = fluoro, methoxy; Scheme 3) phenylboronic acids under conventional heating at 100 °C, producing the desired arylsubstituted aldehydes 13a-c, 14a-c and 15a-c in good yields (Scheme 3), which then followed the same condensation reaction seen before (Scheme 1) for the formation of the oxazolone cycle to obtain compounds 16a-c, 17a-c and 18a-c. Moreover, in order to further support the hypothesized action mechanism of these MAGL inhibitors, the oxazolone ring of the representative compound 18a was opened to verify the key role played by the cyclic portion of these compounds in alkylating the enzyme's catalytic serine by opening the lactone ring. Therefore, compound 18a was hydrolyzed under basic conditions, followed by acidification to obtain biphenylacetamidoacrylic acid derivative 19 21 , which was then submitted to biological assays as a valuable tool for establishing the pharmacophoric portion needed for MAGL inhibition (Scheme 4).
Scheme 4.
Reagents and conditions: a) NaOH 1N, 90 °C, then HCl 3N, 0 °C.
Biological evaluation.
The inhibitory effects of the newly synthesized compounds on human isoforms of MAGL and FAAH (hMAGL and hFAAH) are reported in Table 1 Table 1 ) 10 .
In particular, among the ortho-biphenyl derivatives, the para-fluoro compound 16b was the most Furthermore, in order to verify if the compounds could interact with cysteines of the MAGL enzyme, the activity of the most selective compound 16b was also tested in the presence of the thiol-containing agent 1,4-dithio-DL-threitol (DTT) 22 . As shown in Figure 3A , the hMAGL-IC 50 value of compound 16b was only very slightly influenced by the presence of DTT, shifting from 1.7
M in the absence of DTT to 2.0 M when assayed with 10 M DTT, thus excluding the interaction of these compounds with the cysteine residues of the MAGL enzyme. In order to study the inhibition mechanism of the new reported compounds, the effects of dilution and preincubation on the inhibitory ability of compound 16b were evaluated. In the dilution experiments, if 16b is an irreversible inhibitor, then its inhibition potency should not drop upon dilution, whereas inhibition levels should be substantially reduced upon dilution in the presence of a reversible compound. As shown in Figure 3B , 16b showed reversible inhibition, since the inhibition produced by 40 µM of 11 the compound was significantly higher compared with the inhibition observed with a 40X dilution, which appears similar to that produced by a 1 µM concentration of the compound. In order to further support these results, the activity of 16b was tested at different preincubation times of the inhibitor with the enzyme. In principle, an irreversible inhibitor will increase its capacity to block the enzyme with increasingly longer incubation times in the presence of the enzyme prior to addition of the substrate; a constant IC 50 value, conversely, supports a reversible mechanism 23 . As expected, compound 16b did not show any significant increase in its ability to block MAGL activity after 30 and 60 minutes ( Figure 3C ), suggesting that its binding to MAGL is reversible. These cell lines were selected because of the critical role of MAGL in the tumor progression of breast and ovarian cancers [23] [24] . All three compounds produced appreciable inhibition of cell viability, with IC 50 values ranging from 10.0 to 54.4 µM (see Table 2 ). When compared to the covalent reference inhibitors JZL-184 and CAY10499, compounds 16b-18b showed similar activity profiles, and compound 16b demonstrated an even better overall cytotoxicity on the ovarian cell lines, thus supporting the hypothesis that a reversible MAGL inhibition mechanism could be considered as an interesting approach for studying the MAGL inhibition effects on cancer cell proliferation. Docking studies.
The three most promising ligands (16b, 17b and 18b) and CAY10499 were docked into human MAGL and humanized-rat FAAH using GOLD 5. shown by these compounds for FAAH and, therefore, the great selectivity for MAGL. Conclusions. 15 Chanda and co-workers reported that the genetic MAGL inactivation in mouse models determined a dramatic reduction of the 2-AG hydrolase activity with the consequent presence of elevated 2-AG levels in the nervous system 26 . Furthermore, differently from FAAH, the chronic pharmacological blockade of MAGL determined receptor desensitization and pharmacological tolerance with cross-tolerance to CB 1 cannabinoid receptor agonists, impaired endocannabinoiddependent synaptic plasticity and CB 1 brain receptor desensitization 27 . Taken 
General procedure for the preparation of the oxazole derivatives 2, 3, 4, 16a-c, 17a-c, 18a-c.
A mixture of properly substituted aromatic aldehydes 5, 6, 9, 13a-c, 14a-c or 15a-c (1 eq), Nacetylglycine (1 eq) and sodium acetate (1 eq) in acetic anhydride (5 mL/5 mmol aldehyde) was stirred at reflux for 5 h and then warmed slowly to room temperature over 16 h. The reaction was quenched with water and extracted with AcOEt. The organic layer was washed sequentially with water and saturated brine, dried over Na 2 SO 4 and the solvent was removed under reduced pressure.
The residue was purified with a flash column chromatography using the indicated eluent and pure fractions containing the desired compound were evaporated to dryness affording the desired product.
(Z)-4-Benzylidene-2-methyloxazol-5(4H)-one (2).
yellow crystalline solid, yield: 47% (417.1 mg) from 5. R f = 0.14 (n-hexane/EtOAc 95:5 
(Z)-4-(Furan-2-ylmethylene)-2-methyloxazol-5(4H)-one (3).
bright yellow crystalline solid, yield: 49% (451.2 mg) from 6. R f = 0.18 (n-hexane/EtOAc 9:1). 
(Z)-4-((1-Acetyl-1H-pyrrol-2-yl)methylene)-2-methyloxazol-5(4H)-one (4).
bright yellow crystalline solid, yield: 18% (68.0 mg) from 9. R f = 0.12 (n-hexane/Et 2 O 6:4). 
1-Acetyl-1H-pyrrole-2-carbaldehyde (9).
brown-orange solid, yield: 33% (94.0 mg) from 7. R f = 0.12 (n-hexane/ EtOAc 8:2 
(Z)-4-([1,1'-Biphenyl]-2-ylmethylene)-2-methyloxazol-5(4H)-one (16a).
yellow crystalline solid, yield: 16% (107.0 mg) from 13a. R f = 0.13 (n-hexane/EtOAc 9:1). 
(Z)-4-((4'-Fluoro-[1,1'-biphenyl]-2-yl)methylene)-2-methyloxazol-5(4H)-one (16b).
bright yellow crystalline solid, yield: 24% (137.0 mg) from 13b. R f = 0.14 (n-hexane/EtOAc 95:5 
(Z)-4-((4'-Methoxy-[1,1'-biphenyl]-2-yl)methylene)-2-methyloxazol-5(4H)-one (16c).
bright yellow crystalline solid, yield: 15% (83.3 mg) from 13c. R f = 0.18 (n-hexane/EtOAc 9:1). 
(Z)-4-([1,1'-Biphenyl]-3-ylmethylene)-2-methyloxazol-5(4H)-one (17a).
bright yellow crystalline solid, yield: 43% (530.0 mg) from 14a. R f = 0.15 (n-hexane/EtOAc 95:5). 
(Z)-4-((4'-Methoxy-[1,1'-biphenyl]-3-yl)methylene)-2-methyloxazol-5(4H)-one (17c).
After an initial purification, compound 17c was obtained as a mixture with starting material 14c, therefore this mixture dissolved in dry THF was stirred in the presence of polystyrene sulfonyl hydrazide (PS-TsNHNH 2 , 3 eq relative to aldehyde, minimum capacity 2.2 mmol/g) until disappearance of the starting material. Then the reaction was filtered and washed with THF and the filtrate was evaporated and concentrated under vacuum, to afford a crude residue that was purified by column chromatography.
bright yellow crystalline solid, yield: 17% (94.7 mg) from 14c. R f = 0.21 (n-hexane/EtOAc 9:1). 
(Z)-4-([1,1'-Biphenyl]-4-ylmethylene)-2-methyloxazol-5(4H)-one (18a).
bright yellow crystalline solid, yield: 47% (336.0 mg) from 15a. R f = 0.13 (n-hexane/EtOAc 95:5 
(Z)-4-((4'-Fluoro-[1,1'-biphenyl]-4-yl)methylene)-2-methyloxazol-5(4H)-one (18b).
bright yellow crystalline solid, yield: 22% (154.0 mg) from 15b. R f = 0.18 (n-hexane/EtOAc 9:1). 
(Z)-4-((4'-Methoxy-[1,1'-biphenyl]-4-yl)methylene)-2-methyloxazol-5(4H)-one (18c).
bright yellow crystalline solid, yield: 23% (159.4 mg) from 15c. R f = 0.14 (n-hexane/EtOAc 9:1). 
General procedure for the formation of biphenyl derivatives 13a-c, 14a-c and 15a-c.
A solution of Pd(OAc) 2 (0.03 eq) and triphenylphosphine (0.15 eq) in ethanol (6 mL/2.7 mmol bromo-derivative) and toluene (6 mL/2.7 mmol bromo-derivative) was stirred at RT under nitrogen 21 for 10 min. After that period, commercially available bromo-substituted aldehydes 10-12 (1 eq), 2M
aqueous Na 2 CO 3 (6 mL/2.7 mmol bromo-derivative), and the appropriate substituted phenylboronic acid (1.6 eq) were sequentially added. The resulting mixture was heated at 100 °C in a sealed vial under nitrogen for 24 h. After being cooled to RT, the mixture was diluted with water and extracted with EtOAc. The combined organic phase were dried and concentrated. The crude product was purified by flash chromatography using the indicated eluent and pure fractions containing the desired biphenyl compound were evaporated to dryness affording the desired product. 
4'-Methoxy-[1,1'-biphenyl]-2-carbaldehyde (13c).
light yellow oil, yield: 99% (667.7 mg) from aldehyde 10 and 4-methoxyphenylboronic acid. R f = 0.14 (n-hexane/EtOAc 95:5). 
DTT interference assay
The inhibition assay was the same described above, with the exception that prior to the addition of 40 µL of MAGL (11 ng/well), the compound-substrate mixture was incubated 15 min in the presence of DTT at a 10 µM concentration.
MAGL preincubation assay
The MAGL reaction was conducted at room temperature at a final volume of 200 µL in 10 mM Tris buffer, pH 7.2, containing 1 mM EDTA. A total of 150 µL of MAGL (11 ng/well) was added to 10 µL of DMSO containing the appropriate amount of compound. After 0 min, 30 min, and 60 min of incubation time the reaction was initiated by the addition of 40 µL of 4-NPA 500 µM. The enzyme activity was then measured according to the procedure described above.
MAGL dilution assay
The enzyme (880 ng in 75 µL of Tris buffer, pH 7.2) was incubated during 60 min at room temperature with 5 µL of compound 16b (concentration of 40 µM in the mixture) dissolved in DMSO. The MAGL-inhibitor mixture was then diluted 40-fold with the buffer. After 15 min of incubation, the reaction was initiated on a 160 µL aliquot by the addition of 40 µL of 4-NPA 500 µM and the enzyme activity was measured according to the procedure described above.
FAAH inhibition assay
The IC 50 values for compounds were generated in 96-well microtiter plates. The 
Docking Studies
The ligands were built by means of Maestro 30 and were then minimized in a water environment (using the generalized Born/surface area model) by means of Macromodel 31 . They were minimized using the conjugate gradient, the MMFFs force field, and a distance-dependent dielectric constant of 1.0 until they reached a convergence value of 0.05 kcal Å −1 mol −1 . The ligands were docked using GOLD 5.1 25 in the human MAGL (3JWE 32 PDB code) and the humanized-rat FAAH (3LJ7 33 
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PDB code). The region of interest used by the docking software was defined in such a manner that it contained all the residues that stayed within 15 Å from the ligand in the X-ray structures; the possibility for the ligand to flip ring corners was activated, while the 'allow early termination' command was deactivated. For all the other parameters, the GOLD default ones were used, and the ligands were submitted to 30 genetic algorithm runs. The ChemPLP fitness scoring function was used. For each ligand, the best scored pose was taken into consideration.
